Telix Pharmaceuticals (OTCMKTS:TLPPF) Shares Down 10.7% – Time to Sell?

Telix Pharmaceuticals Limited (OTCMKTS:TLPPF) fell 10.7% during trading on Thursday. The company traded as low as $9.11 and last traded at $9.11. Approximately 1,250 shares changed hands during trading, a decline of 68% from the average daily volume of 3,917 shares. The stock had previously closed at $10.20.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, September 30th. One research analyst has rated the stock with a Buy rating. According to MarketBeat, Telix Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $20.00.

Telix Pharmaceuticals Trading Up 0.4%

The company’s 50-day moving average price is $11.16 and its 200-day moving average price is $10.59.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for cancer imaging and therapy. Its products combine radioactive isotopes with targeting molecules designed to identify or treat specific cancer cells, supporting more personalized approaches to oncology care.

The company’s commercial portfolio includes Illuccix, a gallium-68 gozetotide kit used with positron emission tomography (PET) imaging to help detect prostate-specific membrane antigen (PSMA)-expressing prostate cancer.